SOURCE: Aldagen

December 18, 2007 09:00 ET

Aldagen Appoints Laurence Keller, MD as Chief Medical Officer

DURHAM, NC--(Marketwire - December 18, 2007) - Aldagen, Inc., a biotechnology company advancing a pipeline of clinical-stage regenerative therapies, today announced that Laurence Keller, MD has been appointed as Chief Medical Officer (CMO). Dr. Keller is a board-certified pediatric cardiologist and brings to Aldagen significant experience in leading product development efforts for a broad range of indications.

Prior to joining Aldagen, Dr. Keller was the Senior Medical Director at Kos Pharmaceuticals which was recently acquired by Abbott Laboratories, Inc. At Kos, Larry was responsible for leading the clinical development of products through NDA submission. Dr. Keller was also formerly Senior Director, Clinical Research & Development at Pfizer/Parke Davis where he oversaw drug development for several pediatric and adult product candidates addressing cardiovascular and respiratory indications.

Dr. Keller earned his B.S. degree from The George Washington University and an M.S. degree in Physiology from Georgetown University. He earned his M.D. from The George Washington University and then went on to complete his internship and residency at The New York Hospital-Cornell Medical Center. He did his fellowship training at St. Christopher's Hospital for Children and Children's Hospital of Michigan. Dr. Keller also completed a postdoctoral research fellowship where he studied pulmonary vascular development and angiogenesis. Dr. Keller is a Fellow of the American College of Cardiology and member of the American Heart Association.

"Larry's prior product development accomplishments at large and mid-size pharmaceutical companies will be a great benefit to us as we advance our products through the clinic. His cardiology background will be particularly important as we continue to advance ALD-201 for ischemic heart failure and ALD-301 for critical limb ischemia," said Tom Amick, Chairman and Chief Executive Officer of Aldagen. "We are delighted with his decision to join Aldagen as our CMO and look forward to his contributions toward building a successful portfolio of regenerative medicine products."

"I am thrilled to join a company with such an exciting and promising clinical pipeline of cell therapy products," said Dr. Larry Keller. "Aldagen's products have very promising potential for several serious conditions, and I welcome the opportunity to work with the management team to successfully advance them through clinical development."

About Aldagen, Inc.

ALDAGEN is a biotechnology company advancing a pipeline of clinical-stage regenerative therapies. The Company has three product candidates in clinical development for chronic heart failure, critical limb ischemia and pediatric metabolic disorders and malignancies. ALDAGEN's therapeutics are produced by a proprietary technology platform that selects potent, adult stem and progenitor cells for therapeutic use. The platform yields a broad range of therapeutic cells that can be used rapidly, without culture or expansion. To learn more about ALDAGEN, please visit

Contact Information